Indian Pharma Market October 2021 – IQVIA Report

IPM was valued at Rs. 178,219 Cr for MAT Oct’21. The retail sector was valued at Rs. 151,183 Cr for this period contributing 85% to IPM.

IPM Growth for the month of Oct’21 as compared to the month of Oct’20 was 9.7%. This is the lowest monthly growth in the last 8 months after a low growth of 2.6% reported for Feb’21.

Corresponding to low monthly growth, IPM MAT growth also declined slightly after showing a growing trend consistently for the last 7 months from MAT Feb’21. It reported 17.3% for MAT Oct’21 as compared to 17.8% reported for MAT Sept’21.

At 15657.3 Cr, the monthly sale reported for Oct’21 is the 5th highest sale value in the last 12 months.

New products launched in the last 12 months have clocked a sale of 1459.7 Cr contributing 5.6% to the growth and 0.8% to IPM Value. 

Looking at the last 5 years’ trend, till 2020, chronic segment growth was always higher than acute segment growth. This trend changed in the last few months and now the acute segment growth @20.5% is higher than chronic segment growth of 12.1% for MAT Oct’21.

Anti-Infective, Gastrointestinal, and Vitamins/Minerals/Nutrients are the top drivers of acute segment growth contributing 21.3%, 14.9%, and 12.1% to the segment growth respectively for MAT Oct’21. Overall, they contributed 48.4% to Acute segment growth.

Cardiac, Anti-Diabetic, Neuro/CNS, and Respiratory were the major contributors to Chronic segment growth contributing 32.6%, 17.3%, 15.9%, and 14.8% respectively. Together, these 4 therapies have contributed to 80.6% of chronic segment growth for MAT Oct’21. 

Hetero Healthcare, Corona Remedies, Emcure, J B Chemicals, and Glenmark, are the Top 5 fastest growing among the Top 40 companies in IPM for MAT Oct’21.

J. B. Chemicals & Pharmaceuticals Limited, LA Renon, Macleods, Aristo and Blue Cross are the Top 5 fastest growing companies for the month of Oct’21 out of the Top 40 companies in IPM.

+ Covifor and Cizumab are the major drivers of growth for Hetero contributing 60.4% and 12.1% to its growth, respectively.

+ At month level, major growth drivers for JB Chemicals are Cilacar and Cilacar T contributing 19.9% and 19.8% to growth, respectively. Other top contributing brands to growth are Metrogyl and Rantac contributing 11.2% and 8.9% to growth.

MOVERS AND SHAKERS

In the month of Oct’21 (in comparison to Sep’21), among the TOP 40 companies

+ Pfizer* has gained 2 ranks to reach 16th rank

+ Lupin, Eris* and Cadila have gained 1 rank each to reach 6th, 23rd and 25th

rank.

As per Oct’21 MAT (in comparison to Sep’21 MAT) among the TOP 40 companies

+ Aristo* improved its rank by 1 to reach 11th position. 

Cipremi, Fabiflu, Calpol, Dolo and Zincovit are the top 5 fastest growing brands for MAT Oct’21 among the Top 40 brands in IPM.

+ Calpol, Ryzodeg, Duolin, Dolo and Monocef are the Top 5 fastest growing brands for the month of Oct’21 among the Top 40 brands in IPM.

+ Total number of SKUs with PTR changes in Oct’2021 is 2868.

+ Among the Top 50 Brands of the industry, PTR changes reflected in SKUs of

the following brands : Foracort, Augmentin, Betadine, Clavam, Becosules, Duolin, Volini, Levipil, Zerodol-SP, Seroflo, Gemer & Ecosprin-AV.

Movers & Shakers TSA: Products

Among the Top 40 products as per Oct’21 Month (in comparison to Sep’21 Month)

+ Among the top 10 brands, Pan grew at 25% while Foracort at 16%

+ Liv-52 & Udiliv gained 1 ranks each to secure 9th & 18th position, respectively.

+ Glycomet-GP, Lantus & Novomix gained 2 rank each to secure 3rd, 4th & 12th

position, respectively.

+ Foracort gained 4 ranks to secure 5th position with 16% growth

+ Pan gained 7 ranks to secure 10th position with 25% growth

+ Janumet gained 4 ranks to secure 14th position with 1% growth

+ Duolin gained 5 ranks to secure 16th position with 35% growth

+ Prevenar-13 & Zerodol –SP gained 9 ranks to secure 20th & 22nd position

with 8% & 24% growth, respectively.

+ Pan-D gained 6 ranks to secure 21st position with 8% growth

+ •Volini gained 3 ranks to secure 23rdposition with 1% growth